中文
- Preformulation Studies
- Product Detail
- Company Profile
|
|
|
|
Physicochemical Characterization
Physicochemical characterization is essential for a fundamental understanding of your API and critical to the drug development process. Every regulatory agency requires a certain level of characterization before any clinical trial can be performed. >> |
Solubility Enhancement and Early Formulation Development
We work with our scientific advisory board to establish vehicle platforms and workflows that accurately assess compound solubility (kinetic and equilibrium) and stability so that the proper vehicle >> |
|
Early Solid Form Screening and Selection
We understand that different screenings should be applied to different situations and we work with you to choose the best screening based on the issues with your compound. We will clearly provide options and risk >> |
Risk Assessment
Understanding the physicochemical risks associated with your compound are paramount to successful formulation development. Crystal Pharmatech will systematically evaluate your compound and clearly map out >> |
 |
|
Pharmaceutical companies have clearly recognized the importance of defining the API phase early in the drug development process to ensure late stage development success. They also have incorporated the preformulation workflow early in the lead optimization process to assess the formulation risks of a compound. This new approach significantly speeds up the drug development process and increases efficiency. Our workflows integrate drug discovery and development paradigms to provide you with key information using small amounts of your compound to help you make “go/no go” decisions early in drug development.-
Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.
Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.
Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.
| Request Information |
| Other Products |
| Related Products |
| Recently viewed products |